Can-fite Biopharma
CANF
Can-fite Biopharma (CANF) news
Recent news
Can-Fite Biopharma: Files $100 mln shelf registration statement with SEC - SEC filing
AInvest Wire · 2d agoCan-Fite secures Japanese patent allowance for Namodenoson's anti-obesity technology
Can-Fite BioPharma Ltd. (NYSE American: CANF) has recently secured a patent allowance in Japan for its lead drug candidate, Namodenoson, for its use as an anti-obesity agent. This development follows similar patent approvals in the United States and Australia, further expanding intellectual…
AInvest Wire · Jun 26, 2026ImportantCan-Fite BioPharma ADRs Rise 10% on Patient Outcome on Liver Cancer Treatment
AInvest Wire · Nov 21, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.